A detailed history of First Republic Investment Management, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 19,325 shares of ASND stock, worth $2.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
19,325
Holding current value
$2.59 Million
% of portfolio
0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$86.5 - $103.97 $1.67 Million - $2.01 Million
19,325 New
19,325 $1.81 Million
Q1 2023

May 11, 2023

SELL
$104.9 - $126.78 $11 Million - $13.2 Million
-104,394 Reduced 88.98%
12,929 $1.39 Million
Q4 2022

Feb 13, 2023

BUY
$99.42 - $131.97 $10.2 Million - $13.5 Million
102,323 Added 682.15%
117,323 $14.3 Million
Q3 2022

Nov 03, 2022

BUY
$84.03 - $110.23 $186,126 - $244,159
2,215 Added 17.32%
15,000 $1.55 Million
Q2 2022

Aug 16, 2022

SELL
$78.08 - $117.61 $71,833 - $108,201
-920 Reduced 6.71%
12,785 $1.19 Million
Q1 2022

May 16, 2022

SELL
$102.18 - $135.75 $939,034 - $1.25 Million
-9,190 Reduced 40.14%
13,705 $1.61 Million
Q4 2021

Feb 09, 2022

BUY
$127.1 - $169.66 $178,956 - $238,881
1,408 Added 6.55%
22,895 $3.08 Million
Q3 2021

Nov 12, 2021

BUY
$112.67 - $176.92 $475,467 - $746,602
4,220 Added 24.44%
21,487 $3.43 Million
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $1.22 Million - $1.46 Million
10,017 Added 138.17%
17,267 $2.27 Million
Q1 2021

May 14, 2021

SELL
$124.92 - $173.33 $8.81 Million - $12.2 Million
-70,538 Reduced 90.68%
7,250 $934,000
Q4 2020

Feb 16, 2021

BUY
$151.2 - $182.76 $4.09 Million - $4.94 Million
27,057 Added 53.33%
77,788 $13 Million
Q3 2020

Nov 12, 2020

BUY
$134.29 - $154.32 $6.21 Million - $7.13 Million
46,229 Added 1026.85%
50,731 $7.83 Million
Q2 2020

Aug 13, 2020

BUY
$110.87 - $156.01 $499,136 - $702,357
4,502 New
4,502 $666,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.49B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.